Current Report Filing (8-k)
January 20 2023 - 4:32PM
Edgar (US Regulatory)
0001508381
false
0001508381
2023-01-19
2023-01-19
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES |
SECURITIES AND EXCHANGE COMMISSION |
WASHINGTON, DC 20549 |
|
FORM 8-K |
CURRENT REPORT PURSUANT |
TO SECTION 13 OR 15(D) OF THE |
SECURITIES EXCHANGE ACT OF 1934 |
|
Date
of report (Date of earliest event reported): January 19, 2023 |
BIONIK
LABORATORIES CORP.
(Exact Name of Registrant
as Specified in Its Charter)
Delaware |
|
000-54717 |
|
27-1340346 |
(State or Other Jurisdiction of
Incorporation or Organization) |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
80
Coolidge Hill Road
Watertown, MA |
|
02472 |
(Address of Principal Executive Offices) |
|
(Zip Code) |
Registrant’s Telephone Number,
Including Area Code: (617) 926-4800
(Former Name or Former
Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). |
|
Emerging growth company ¨ |
|
If an emerging growth
company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new
or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨ |
|
Securities registered pursuant to Section 12(b) of the Act:
Title of each
class |
Trading Symbol |
Name of each
exchange on which registered |
Not applicable |
Not applicable |
Not applicable |
Item 5.07 Submission of Matters to a Vote of Security Holders
The Annual Meeting of Stockholders (the “Annual
Meeting”) of Bionik Laboratories Corp. (the “Company”) was held on January 19, 2023. At the Annual Meeting, the stockholders
of the Company voted on the following two proposals and cast their votes as described below. The proposals are described in more detail
in the Company’s Definitive Proxy Statement on Schedule 14A filed with the U.S. Securities and Exchange Commission on December 7,
2022.
Proposal 1: Election of the seven nominees
listed below to serve on the Board of Directors of the Company until the next Annual Meeting of Stockholders and until their respective
successors have been duly elected and qualified:
Nominee |
For |
Withhold Authority |
Broker Non-votes |
Andre Auberton-Herve |
3,489,934 |
7,803 |
75,827 |
Remi Gaston-Dreyfus |
3,490,768 |
6,969 |
75,827 |
Rich Russo Jr. |
3,493,270 |
4,467 |
75,827 |
Joseph Martin |
3,490,768 |
6,969 |
75,827 |
Charles Matine |
3,490,768 |
6,969 |
75,827 |
Audrey Thevenon |
3,490,768 |
6,969 |
75,827 |
Michal Prywata |
3,490,768 |
6,969 |
75,827 |
Proposal 2: To ratify MNP, LLP as the Company’s
independent public accountants for the year ending March 31, 2023.
For |
Against |
Abstain |
3,566,547 |
5,337 |
1,680 |
Item
9.01 Financial Statements and Exhibits.
Exhibit |
|
Description |
104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.
Date: January 20, 2023
|
BIONIK LABORATORIES CORP. |
|
|
|
|
By: |
/s/ Rich Russo Jr. |
|
Name: |
Rich Russo Jr. |
|
Title: |
Chief Executive Officer |
Bionik Laboratories (CE) (USOTC:BNKL)
Historical Stock Chart
From Nov 2024 to Dec 2024
Bionik Laboratories (CE) (USOTC:BNKL)
Historical Stock Chart
From Dec 2023 to Dec 2024